Profile
F.
Andrew Dorr served as the Chief Medical Officer at Ionis Pharmaceuticals, Inc. from 1996 to 2003.
He then worked as the Chief Operating Officer at Salmedix, Inc. in 2004.
Later, he became the Chief Medical Officer at Spyre Therapeutics, Inc. Dr. Dorr received his undergraduate degree from Davidson College and his doctorate from The University of North Carolina at Charlotte.
Former positions of F. Andrew Dorr
| Companies | Position | End |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 20/04/2017 |
Salmedix, Inc.
 Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Chief Operating Officer | 31/07/2004 |
| IONIS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2002 |
Training of F. Andrew Dorr
| Davidson College | Undergraduate Degree |
| The University of North Carolina at Charlotte | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Salmedix, Inc.
Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- F. Andrew Dorr
